Reaction Details Report a problem with these data
Target
Sodium- and chloride-dependent glycine transporter 2
Ligand
BDBM50322441
Substrate
n/a
Meas. Tech.
ChEMBL_643223 (CHEMBL1177034)
EC50
>30000±n/a nM
Citation
Pinard, E; Alanine, A; Alberati, D; Bender, M; Borroni, E; Bourdeaux, P; Brom, V; Burner, S; Fischer, H; Hainzl, D; Halm, R; Hauser, N; Jolidon, S; Lengyel, J; Marty, HP; Meyer, T; Moreau, JL; Mory, R; Narquizian, R; Nettekoven, M; Norcross, RD; Puellmann, B; Schmid, P; Schmitt, S; Stalder, H; Wermuth, R; Wettstein, JG; Zimmerli, D Selective GlyT1 inhibitors: discovery of [4-(3-fluoro-5-trifluoromethylpyridin-2-yl)piperazin-1-yl][5-methanesulfonyl-2-((S)-2,2,2-trifluoro-1-methylethoxy)phenyl]methanone (RG1678), a promising novel medicine to treat schizophrenia. J Med Chem 53:4603-14 (2010) [PubMed] Article
More Info.:
Target
Name:
Sodium- and chloride-dependent glycine transporter 2
Synonyms:
GLYT2 | Glycine transporter 2 | NET1 | SC6A5_HUMAN | SLC6A5 | Sodium- and chloride-dependent glycine transporter 2
Type:
Enzyme Catalytic Domain
Mol. Mass.:
87438.56
Organism:
Homo sapiens (Human)
Description:
Glycine-2-transporter 0 HUMAN::Q9Y345
Residue:
797
Sequence:
MDCSAPKEMNKLPANSPEAAAAQGHPDGPCAPRTSPEQELPAAAAPPPPRVPRSASTGAQTFQSADARACEAERPGVGSCKLSSPRAQAASAALRDLREAQGAQASPPPGSSGPGNALHCKIPFLRGPEGDANVSVGKGTLERNNTPVVGWVNMSQSTVVLATDGITSVLPGSVATVATQEDEQGDENKARGNWSSKLDFILSMVGYAVGLGNVWRFPYLAFQNGGGAFLIPYLMMLALAGLPIFFLEVSLGQFASQGPVSVWKAIPALQGCGIAMLIISVLIAIYYNVIICYTLFYLFASFVSVLPWGSCNNPWNTPECKDKTKLLLDSCVISDHPKIQIKNSTFCMTAYPNVTMVNFTSQANKTFVSGSEEYFKYFVLKISAGIEYPGEIRWPLALCLFLAWVIVYASLAKGIKTSGKVVYFTATFPYVVLVILLIRGVTLPGAGAGIWYFITPKWEKLTDATVWKDAATQIFFSLSAAWGGLITLSSYNKFHNNCYRDTLIVTCTNSATSIFAGFVIFSVIGFMANERKVNIENVADQGPGIAFVVYPEALTRLPLSPFWAIIFFLMLLTLGLDTMFATIETIVTSISDEFPKYLRTHKPVFTLGCCICFFIMGFPMITQGGIYMFQLVDTYAASYALVIIAIFELVGISYVYGLQRFCEDIEMMIGFQPNIFWKVCWAFVTPTILTFILCFSFYQWEPMTYGSYRYPNWSMVLGWLMLACSVIWIPIMFVIKMHLAPGRFIERLKLVCSPQPDWGPFLAQHRGERYKNMIDPLGTSSLGLKLPVKDLELGTQC